Immunotherapy in non-small cell lung cancer: current status, advances and challenges

被引：0

作者：

Tartarone, Alfredo ^{[1
]}

Lerose, Rosa ^{[2
]}

Tartarone, Marina ^{[3
]}

机构：

[1] IRCCS CROB Referral Canc Ctr Basilicata, Dept Onco Hematol, Div Med Oncol, Via Padre Pio 1, I-85028 Rionero In Vulture, Potenza, Italy

[2] IRCCS CROB Referral Canc Ctr Basilicata, Hosp Pharm, Rionero In Vulture, Potenza, Italy

[3] Humanitas Univ, Milan, Italy

来源：

MINERVA RESPIRATORY MEDICINE | 2024年 / 63卷 / 03期

关键词：

Carcinoma; non-small-cell lung; Immunotherapy; Immune checkpoint inhibitors; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; 1ST-LINE TREATMENT; BRAIN METASTASES; POOLED ANALYSIS; CHECKMATE; 9LA; PEMBROLIZUMAB; CHEMOTHERAPY; DOCETAXEL; PHASE-3;

D O I：

10.23736/S2784-8477.24.02108-9

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

In recent years, thanks to the advent of immunotherapy, the therapeutic landscape of non-oncogene-addicted non-small cell lung cancer (NSCLC) has undergone a complete revolution. So far, several monoclonal antibodies directed against PD-1, PD-L1, or CTLA-4, known as immune checkpoint inhibitors (ICIs), administered alone or in combination with other agents have shown efficacy in metastatic setting as well as, more recently, even in the early-stage. We reviewed the role of immunotherapy in NSCLC focusing the attention not only on the results of the main currently available clinical trials but also on novel combination strategies.

引用

页码：110 / 120

页数：11

共 53 条

[11] Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer [J].

Fehrenbacher, Louis ;

von Pawel, Joachim ;

Park, Keunchil ;

Rittmeyer, Achim ;

Gandara, David R. ;

Aix, Santiago Ponce ;

Han, Ji-Youn ;

Gadgeel, Shirish M. ;

Hida, Toyoaki ;

Cortinovis, Diego L. ;

Cobo, Manuel ;

Kowalski, Dariusz M. ;

De Marinis, Filippo ;

Gandhi, Mayank ;

Danner, Bradford ;

Matheny, Christina ;

Kowanetz, Marcin ;

He, Pei ;

Felizzi, Federico ;

Patel, Hina ;

Sandler, Alan ;

Ballinger, Marcus ;

Barlesi, Fabrice .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :1156-1170

[12] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].

Fehrenbacher, Louis ;

Spira, Alexander ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

Vansteenkiste, Johan ;

Mazieres, Julien ;

Park, Keunchil ;

Smith, David ;

Artal-Cortes, Angel ;

Lewanski, Conrad ;

Braiteh, Fadi ;

Waterkamp, Daniel ;

He, Pei ;

Zou, Wei ;

Chen, Daniel S. ;

Yi, Jing ;

Sandler, Alan ;

Rittmeyer, Achim .

LANCET, 2016, 387 (10030) :1837-1846

[13] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial [J].

Felip, Enriqueta ;

Altorki, Nasser ;

Zhou, Caicun ;

Csoszi, Tibor ;

Vynnychenko, Ihor ;

Goloborodko, Oleksandr ;

Luft, Alexander ;

Akopov, Andrey ;

Martinez-Marti, Alex ;

Kenmotsu, Hirotsugu ;

Chen, Yuh-Min ;

Chella, Antonio ;

Sugawara, Shunichi ;

Voong, David ;

Wu, Fan ;

Yi, Jing ;

Deng, Yu ;

McCleland, Mark ;

Bennett, Elizabeth ;

Gitlitz, Barbara ;

Wakelee, Heather .

LANCET, 2021, 398 (10308) :1344-1357

[14] CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations [J].

Felip, Enriqueta ;

Ardizzoni, Andrea ;

Ciuleanu, Tudor ;

Cobo, Manuel ;

Laktionov, Konstantin ;

Szilasi, Maria ;

Califano, Raffaele ;

Carcereny, Enric ;

Griffiths, Richard ;

Paz-Ares, Luis ;

Duchnowska, Renata ;

Alonso Garcia, Miriam ;

Isla, Dolores ;

Jassem, Jacek ;

Appel, Wiebke ;

Milanowski, Janusz ;

Van Meerbeeck, Jan P. ;

Wolf, Juergen ;

Li, Ang ;

Acevedo, Angelic ;

Popat, Sanjay .

EUROPEAN JOURNAL OF CANCER, 2020, 127 :160-172

[15] Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [J].

Forde, Patrick M. ;

Spicer, Jonathan ;

Lu, Shun ;

Provencio, Mariano ;

Mitsudomi, Tetsuya ;

Awad, Mark M. ;

Felip, Enriqueta ;

Broderick, Stephen R. ;

Brahmer, Julie R. ;

Swanson, Scott J. ;

Kerr, Keith ;

Wang, Changli ;

Ciuleanu, Tudor-Eliade ;

Saylors, Gene B. ;

Tanaka, Fumihiro ;

Ito, Hiroyuki ;

Chen, Ke-Neng ;

Liberman, Moishe ;

Vokes, Everett E. ;

Taube, Janis M. ;

Dorange, Cecile ;

Cai, Junliang ;

Fiore, Joseph ;

Jarkowski, Anthony ;

Balli, David ;

Sausen, Mark ;

Pandya, Dimple ;

Calvet, Christophe Y. ;

Girard, Nicolas .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21) :1973-1985

[16] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[17] Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study [J].

Garassino, Marina C. ;

Gadgeel, Shirish ;

Speranza, Giovanna ;

Felip, Enriqueta ;

Esteban, Emilio ;

Domine, Manuel ;

Hochmair, Maximilian J. ;

Powell, Steven F. ;

Bischoff, Helge G. ;

Peled, Nir ;

Grossi, Francesco ;

Jennens, Ross R. ;

Reck, Martin ;

Hui, Rina ;

Garon, Edward B. ;

Kurata, Takayasu ;

Gray, Jhanelle E. ;

Schwarzenberger, Paul ;

Jensen, Erin ;

Pietanza, M. Catherine ;

Rodriguez-Abreu, Delvys .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) :1992-+

[18] Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer [J].

Grossi, Francesco ;

Genova, Carlo ;

Crino, Lucio ;

Delmonte, Angelo ;

Turci, Daniele ;

Signorelli, Diego ;

Passaro, Antonio ;

Parra, Hector Soto ;

Catino, Annamaria ;

Landi, Lorenza ;

Gelsomino, Francesco ;

Tiseo, Marcello ;

Puppo, Gianfranco ;

Roila, Fausto ;

Ricciardi, Serena ;

Tonini, Giuseppe ;

Cognetti, Francesco ;

Toschi, Luca ;

Tassinari, Davide ;

Scoppola, Alessandro ;

Giannarelli, Diana ;

Cortesi, Enrico .

EUROPEAN JOURNAL OF CANCER, 2019, 123 :72-80

[19] Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC [J].

Herbst, Roy S. ;

Giaccone, Giuseppe ;

de Marinis, Filippo ;

Reinmuth, Niels ;

Vergnenegre, Alain ;

Barrios, Carlos H. ;

Morise, Masahiro ;

Felip, Enriqueta ;

Andric, Zoran ;

Geater, Sarayut ;

Ozguroglu, Mustafa ;

Zou, Wei ;

Sandler, Alan ;

Enquist, Ida ;

Komatsubara, Kimberly ;

Deng, Yu ;

Kuriki, Hiroshi ;

Wen, Xiaohui ;

McCleland, Mark ;

Mocci, Simonetta ;

Jassem, Jacek ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) :1328-1339

[20] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

← 1 2 3 4 5 6 →